Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 4666 AL 4680

Novel approaches to increase synaptic resilience as potential treatments for Alzheimer's disease

Pham AQ, Dore K.

Semin Cell Dev Biol. 2023 Apr;139:84-92. doi: 10.1016/j.semcdb.2022.03.032. Epub 2022 Mar 31.

Diverse pathways to neuronal necroptosis in Alzheimer's disease

Jayaraman A, Reynolds R.

Eur J Neurosci. 2022 Nov;56(9):5428-5441. doi: 10.1111/ejn.15662. Epub 2022 Apr 9.

Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review

Azam MS, Wahiduzzaman M, Reyad-Ul-Ferdous M, Islam MN, Roy M.

Pharm Res. 2022 Apr;39(4):611-629. doi: 10.1007/s11095-022-03237-7. Epub 2022 Apr 4.

The dawn of disease modification for Alzheimer's disease: Hope and peril

Tan ZS.

J Am Geriatr Soc. 2022 Jun;70(6):1661-1663. doi: 10.1111/jgs.17774. Epub 2022 Apr 5.

Ginkgolides and Huperzine A for complementary treatment of Alzheimer's disease

Villegas C, Perez R, Petiz LL, Glaser T, Ulrich H, Paz C.

IUBMB Life. 2022 Aug;74(8):763-779. doi: 10.1002/iub.2613. Epub 2022 Apr 5.

Transcriptional landscape of human microglia implicates age, sex, and APOE-related immunometabolic pathway perturbations

Patel T, Carnwath TP, Wang X, Allen M, Lincoln SJ, Lewis-Tuffin LJ, Quicksall ZS, Lin S, Tutor-New FQ, Ho CCG, Min Y, Malphrus KG, Nguyen TT, Martin E, Garcia CA, Alkharboosh RM, Grewal S, Chaichana K, Wharen R, Guerrero-Cazares H, Quinones-Hinojosa A, Ertekin-Taner N.

Aging Cell. 2022 May;21(5):e13606. doi: 10.1111/acel.13606. Epub 2022 Apr 6.

Dissecting the clinical heterogeneity of early-onset Alzheimer's disease

Sirkis DW, Bonham LW, Johnson TP, La Joie R, Yokoyama JS.

Mol Psychiatry. 2022 Jun;27(6):2674-2688. doi: 10.1038/s41380-022-01531-9. Epub 2022 Apr 7.

Preparing future health care workers for interactions with people with dementia: A mixed methods study

Torrence C, Bhanu A, Bertrand J, Dye C, Truong K, Madathil KC.

Gerontol Geriatr Educ. 2023 Apr-Jun;44(2):223-242. doi: 10.1080/02701960.2022.2042805. Epub 2022 Apr 8.

Oxidative stress: The core pathogenesis and mechanism of Alzheimer's disease

Bai R, Guo J, Ye XY, Xie Y, Xie T.

Ageing Res Rev. 2022 May;77:101619. doi: 10.1016/j.arr.2022.101619. Epub 2022 Apr 5.

γ-Secretase in Alzheimer's disease

Hur JY.

Exp Mol Med. 2022 Apr;54(4):433-446. doi: 10.1038/s12276-022-00754-8. Epub 2022 Apr 8.

Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease

Kumar N, Kumar V, Anand P, Kumar V, Ranjan Dwivedi A, Kumar V.

Bioorg Med Chem. 2022 May 1;61:116742. doi: 10.1016/j.bmc.2022.116742. Epub 2022 Apr 5.

Association Study and Meta-Analysis of Polymorphisms and Blood mRNA Expression of the ALDH2 Gene in Patients with Alzheimer's Disease

Ueno M, Yoshino Y, Mori H, Funahashi Y, Kumon H, Ochi S, Ozaki T, Tachibana A, Yoshida T, Shimizu H, Mori T, Iga JI, Ueno SI.

J Alzheimers Dis. 2022;87(2):863-871. doi: 10.3233/JAD-215627.

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab

Korthauer LE, Giugliano RP, Guo J, Sabatine MS, Sever P, Keech A, Atar D, Kurtz C, Ruff CT, Mach F, Ott BR.

PLoS One. 2022 Apr 11;17(4):e0266615. doi: 10.1371/journal.pone.0266615. eCollection 2022.

Strain-specific pre-existing immunity: A key to understanding the role of chronic Toxoplasma infection in cognition and Alzheimer's diseases?

Xiao J, Savonenko A, Yolken RH.

Neurosci Biobehav Rev. 2022 Jun;137:104660. doi: 10.1016/j.neubiorev.2022.104660. Epub 2022 Apr 9.

Microglial Endocannabinoid Signalling in AD

Scipioni L, Ciaramellano F, Carnicelli V, Leuti A, Lizzi AR, De Dominicis N, Oddi S, Maccarrone M.

Cells. 2022 Apr 6;11(7):1237. doi: 10.3390/cells11071237.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias